Pediatric Cancer Studies Triggered by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) Aim at Labels, Not at Improved Treatment

被引：0
|
作者：
Rose, K. [1 ]
机构：
[1] Klausrose Consulting, Med Sci, CH-4125 Riehen, Switzerland
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V409 SIOP1
引用
收藏
页码：S361 / S362
页数：2
相关论文
共 50 条
  • [41] The role of Clinical Outcome Assessment (COA) data in the drug approval process of medicines for the treatment of Restless Legs Syndrome (RLS): A review of the labels of medicines approved by the FDA and the EMA
    Anfray, C.
    Perrier, L. -L.
    Bindi, P.
    Acquadro, C.
    Emery, M. P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 177 - 177
  • [42] FDA Labeling Of Antiepileptic Drugs (AEDs) For Partial Onset Seizures (POS) Challenges The European Medicines Agency's (EMA) Pediatric Investigation Plan (PIP) Concept
    Rose, Klaus
    EUROPEAN JOURNAL OF PEDIATRICS, 2017, 176 (11) : 1458 - 1459
  • [43] Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
    Nicolò Schifano
    Paolo Capogrosso
    Luca Boeri
    Giuseppe Fallara
    Stefania Chiappini
    Matthew Rewhorn
    Omer Onur Cakir
    Hannah Harvey
    Fabio Castiglione
    Hussain M. Alnajjar
    Asif Muneer
    Federico Deho’
    Fabrizio Schifano
    Francesco Montorsi
    Andrea Salonia
    International Journal of Impotence Research, 2023, 35 : 465 - 471
  • [44] Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
    Schifano, Nicolo
    Capogrosso, Paolo
    Boeri, Luca
    Fallara, Giuseppe
    Chiappini, Stefania
    Rewhorn, Matthew
    Cakir, Omer Onur
    Harvey, Hannah
    Castiglione, Fabio
    Alnajjar, Hussain M.
    Muneer, Asif
    Deho', Federico
    Schifano, Fabrizio
    Montorsi, Francesco
    Salonia, Andrea
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2023, 35 (05) : 465 - 471
  • [45] Approval Timelines for Advanced Therapeutics in Inflammatory Bowel Disease: A Comparison Between the European Medicines Agency and the Food and Drug Administration
    Hanzel, Jurij
    Ma, Christopher
    De Silva, Theshani Amalka
    Alphonsus, Lotus
    Guizzetti, Leonardo
    Crowley, Eileen
    Singh, Siddharth
    Jairath, Vipul
    INFLAMMATORY BOWEL DISEASES, 2023, 30 (07) : 1211 - 1214
  • [46] Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval
    Joppi, Roberta
    Bertele, Vittorio
    Vannini, Tommaso
    Garattini, Silvio
    Banzi, Rita
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (01) : 170 - 174
  • [47] Food-Drug Effects and Pediatric Drug Development Studies Submitted to the US Food and Drug Administration, 2012-2022
    Tunehag, Kayla R.
    George, Blessy
    Samuels, Sherbet
    Vo, Karen
    Arya, Vikram
    Abulwerdi, Gelareh
    Burckart, Gilbert J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (06): : 697 - 703
  • [48] Transparency in European Medicines Agency and US Food and Drug Administration Decision Making: Is It Possible to Identify the Rationale for Divergences in Approved Indication From Public Assessment Reports?
    Bujar, Magda
    Ferragu, Sara
    McAuslane, Neil
    Liberti, Lawrence
    Kuhler, Thomas C.
    CLINICAL THERAPEUTICS, 2021, 43 (05) : 888 - 905
  • [49] Comparison of published core outcome sets with outcomes recommended in regulatory guidance from the US Food and Drug Administration and European Medicines Agency: cross sectional analysis
    Saldanha, Ian J.
    Dodd, Susanna
    Fish, Rebecca
    Gorst, Sarah L.
    Hall, Deborah A.
    Jacobsen, Pamela
    Kirkham, Jamie J.
    Trepel, Dominic
    Williamson, Paula R.
    BMJ MEDICINE, 2022, 1 (01):
  • [50] Exposure-Response Assessment in Pediatric Drug Development Studies Submitted to the US Food and Drug Administration
    Zhang, Yifei
    Wang, Yaning
    Khurana, Mona
    Sachs, Hari Cheryl
    Zhu, Hao
    Burckart, Gilbert J.
    Alexander, John
    Yao, Lynne P.
    Wang, Jian
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (01) : 90 - 98
12345